Telbivudine versus lamivudine in patients with chronic hepatitis B

Telbivudine versus lamivudine in patients with chronic hepatitis B

BACKGROUND: Reducing hepatitis B virus (HBV) replication to minimal levels is emerging as a key therapeutic goal for chronic hepatitis B. METHODS: In this double-blind, phase 3 trial, 1370 patients with chronic hepatitis B were randomly assigned to receive 600 mg of telbivudine or 100 mg of lamivudi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ching Lung Lai, Edward Gane, Yun Fan Liaw, Chao Wei Hsu, Satawat Thongsawat, Yuming Wang, Yagang Chen, E. Jenny Heathcote, Jens Rasenack, Natalie Bzowej, Nikolai V. Naoumov, Adrian M. Di Bisceglie, Stefan Zeuzem, Young Myoung Moon, Zachary Goodman, George Chao, Barbara Fielman Constance, Nathaniel A. Brown
Format:	Journal
Published:	2018
Subjects:	Medicine
Online Access:	https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=37349120537&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/61227
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	Chiang Mai University

Similar Items

Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B
by: Zeuzem, S., et al.
Published: (2016)

Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B
by: Edward J. Gane, et al.
Published: (2018)

Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B
by: Y. Wang, et al.
Published: (2018)

Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B
by: Wang Y., et al.
Published: (2014)

Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B
by: Y. Wang, et al.
Published: (2018)

Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B
by: Gane E., et al.
Published: (2017)

Treatment of hepatitis B e antigen-positive chronic hepatitis with telbivudine or adefovir: A randomized trial
by: Chan, H.L.Y., et al.
Published: (2016)

Evaluation of one-year lamivudine and telbivudine therapy on chronic hepatitis b patients: Based on biochemical, virological and fibrosis status in dr. soetomo general hospital
by: Ummi Maimunah, et al.
Published: (2019)

Evaluation of one year lamivudine and telbivudine therapy on chronic hepatitis b patient: Based on biochemical, virological and fibrosis status in dr. soetomo general hospital
by: Ummi Maimunah, et al.
Published: (2019)

EVALUASI PEMBERIAN TERAPI LAMIVUDIN DAN TELBIVUDIN PADA PASIEN HEPATITIS B KRONIS DI RSUD DR. SOETOMO SURABAYA PADA PERIODE TERAPI 2014 – 2015
by: Erik Geraldus Edison, NIM011511133143
Published: (2018)

Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy
by: Marcellin Patrick, et al.
Published: (2016)

Telbivudine: A hepatitis B-specific antiviral
by: Lim, S.G.
Published: (2011)

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
by: George K.K. Lau, et al.
Published: (2018)

Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: Results from the 2-year roadmap strategy
by: Teerha Piratvisuth, et al.
Published: (2018)

Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: Pharmacodynamic implications
by: Zhou, X.-J., et al.
Published: (2016)

Lamivudine (3-TC)
by: จิราภรณ์ อังวิทยาธร
Published: (2020)

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
by: Lau G.K.K., et al.
Published: (2014)

Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens
by: Weerawat Manosuthi, et al.
Published: (2018)

Developmental pharmacokinetic changes of lamivudine in infants and children
by: Adriana H. Tremoulet, et al.
Published: (2018)

Developmental pharmacokinetic changes of lamivudine in infants and children
by: Tremoulet A.H., et al.
Published: (2014)

Ragaman Genetik Gen Polimerase Virus Hepatitis B Pada Pasien Hepatitis B Kronik dengan Pengobatan Telbivudine
by: Mastutik, Gondo, et al.
Published: (2015)

Metabolic benefits of switching to tenofovir/lamivudine after long-term use of stavudine/lamivudine in NNRTI-based antiretroviral regimens: A prospective study
by: Weerawat Manosuthi, et al.
Published: (2018)

PENGARUH SIMETIDIN TERHADAP ABSORPSI LAMIVUDIN PADA KELINCI
by: Aniek Setiya Budiatin, Dra., M.Si., Apt., et al.
Published: (2005)

PENGARUH SIMETIDIN TERHADAP ABSORPSI LAMIVUDIN PADA KELINCI
by: Aniek Setiya Budiatin, Dra. M.Si., Apt, et al.
Published: (2008)

Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients
by: Lim, L.L., et al.
Published: (2016)

Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients
by: Lim, L.L., et al.
Published: (2014)

A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients
by: Chaiwat Ungsedhapand, et al.
Published: (2018)

Biowaiver monographs for immediate release solid oral dosage forms: Lamivudine
by: S. Strauch, et al.
Published: (2018)

Four years of lamivudine treatment in Chinese patients with chronic hepatitis B
by: Chang, T.-T., et al.
Published: (2016)

Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics
by: Dan, Y.-Y., et al.
Published: (2011)

Outcome of lamivudine-resistant hepatitis B virus is generally benign except in cirrhotics
by: Dan, Y.-Y., et al.
Published: (2016)

Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents
by: Linda Aurpibul, et al.
Published: (2018)

Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients
by: Naïm Bouazza, et al.
Published: (2018)

Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents
by: Linda Aurpibul, et al.
Published: (2018)

Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients
by: Naïm Bouazza, et al.
Published: (2018)

Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents
by: Aurpibul L., et al.
Published: (2017)

Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients
by: Bouazza N., et al.
Published: (2017)

Development and validation of an oligonucleotide ligation assay to detect lamivudine resistance in hepatitis B virus
by: Ingrid A. Beck, et al.
Published: (2018)

Development and validation of an oligonucleotide ligation assay to detect lamivudine resistance in hepatitis B virus
by: Beck I., et al.
Published: (2017)

Adefovir dipivoxil as the rescue therapy for lamivudine-resistant hepatitis B post liver transplant
by: Wai, C.-T., et al.
Published: (2012)